75 completed, 10 unknown, 6 terminated, 4 recruiting. 102 Phase 3, 13 Phase 2.
Follow Ankylosis: new trials by email Literature Review of Ankylosis trials Research Report on Ankylosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) 608, Placebo - Axial Spondyloarthritis, Non-Radiographic | Phase 3 | Not yet recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 380 | 2026-03-09 | 2026-01-16 |
| Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis Xeligekimab injection - Nr-axial Spondyloarthritis, Non-Radiographical Axial Spondyloarthritis | Phase 2 / Phase 3 | Not yet recruiting | Lingli Dong | 40 | 2026-01-31 | 2026-01-14 |
| A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) 608 dose, Placebo - Ankylosing Spondylitis | Phase 3 | Recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 500 | 2025-11-07 | 2025-12-10 |
| A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis LNK01001, Placebo - Ankylosing Spondylitis | Phase 3 | Recruiting | Lynk Pharmaceuticals Co., Ltd | 352 | 2025-08-29 | 2026-11-12 |
| The Efficacy of Fecal Microbiota Transplatation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment active FMT, Placebo - Axial Spondyloarthritis | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 20 | 2024-03-28 | 2024-04-09 |
| Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA) anti-TRBV9 monoclonal antibody infusions, Placebo infusions, Adalimumab subcutaneous injection - Axial Spondyloarthritis | Phase 3 | Active not recruiting | Biocad | 421 | 2023-12-25 | 2024-06-03 |
| A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis AK111, Placebo+AK111 - Ankylosing Spondylitis | Phase 3 | Completed | Akeso | 510 | 2023-11-22 | 2026-10-16 |
| Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS) Jaktinib - Ankylosing Spondylitis | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 207 | 2023-11-10 | 2026-09-24 |
| A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo Jitongning tablets, a simulated agent of Jitongning tablets - Ankylosing Spondylitis | Phase 3 | Recruiting | Tasly Pharmaceutical Group Co., Ltd | 408 | 2023-09-11 | 2024-11-21 |
| Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS) Jaktinib, Placebo - Ankylosing Spondylitis | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 265 | 2023-07-20 | 2026-09-22 |
| A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis Filgotinib, Placebo - Axial Spondyloarthritis | Phase 3 | Active not recruiting | Alfasigma S.p.A. | 495 | 2023-04-05 | 2025-12-04 |
| Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis Netakimab, Placebo - Ankylosing Spondylitis | Phase 3 | Completed | SPH-BIOCAD (HK) Limited | 113 | 2023-03-20 | 2025-12-11 |
| A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis SHR0302, SHR0302 placebo - Non-radiographic Axial Spondyloarthritis | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 300 | 2022-08-16 | 2022-09-02 |
| Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis GR1501 low dose, GR1501 high dose, placebo - Axial Spondyloarthritis | Phase 3 | Completed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 465 | 2022-06-13 | 2024-09-25 |
| Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis Secukinumab, Placebo - Non-radiographic Axial Spondyloarthritis | Phase 3 | Completed | Novartis Pharmaceuticals | 137 | 2021-07-21 | 2026-04-09 |
| Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis SHR-1314, Placebo - Ankylosing Spondylitis | Phase 2 / Phase 3 | Completed | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 548 | 2021-06-09 | 2024-05-22 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy Filgotinib, Placebo to Match Filgotinib - Ankylosing Spondylitis | Phase 3 | Withdrawn | Gilead Sciences | 2020-12-01 | 2021-01-11 | |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy Filgotinib, Placebo to Match Filgotinib - Ankylosing Spondylitis | Phase 3 | Withdrawn | Gilead Sciences | 2020-12-01 | 2021-01-11 | |
| A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis SHR0302, SHR0302 placebo - Ankylosing Spondylitis | Phase 2 / Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 504 | 2020-10-14 | 2023-07-27 |
| A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis Bimekizumab - Axial Spondyloarthritis, Ankylosing Spondylitis | Phase 3 | Completed | UCB Biopharma SRL | 508 | 2020-06-16 | 2026-11-05 |
Showing 20 of 102. Sign in to see all of them.
Spondylitis, Ankylosing (82) · Axial Spondyloarthritis (26) · Spondylarthritis (12) · Non-Radiographic Axial Spondyloarthritis (10) · Spondylarthropathies (8) · Arthritis (6) · Spinal Diseases (4) · Spondylitis (4) · Arthritis, Juvenile (3) · Arthritis, Rheumatoid (3) · Osteoarthritis (3) · Arthritis, Psoriatic (2) · Musculoskeletal Diseases (2) · Sacroiliitis (2)
Joint Diseases (101) · Bone Diseases (100) · Musculoskeletal Diseases (100) · Spinal Diseases (97) · Spondylitis (96) · Arthritis (95) · Spondylarthropathies (92) · Spondylarthritis (88) · Axial Spondyloarthritis (74) · Immune System Diseases (6) · Rheumatic Diseases (6) · Skin and Connective Tissue Diseases (6) · Autoimmune Diseases (5) · Connective Tissue Diseases (5)
secukinumab (14) · Adalimumab (13) · Etanercept (7) · golimumab (7) · Infliximab (6) · ixekizumab (6) · GLPG0634 (3) · bimekizumab (3) · Celecoxib (2) · Certolizumab Pegol (2) · Etoricoxib (2) · Meloxicam (2) · Methotrexate (2) · Naproxen (2) · Ustekinumab (2)
Novartis Pharmaceuticals (14) · Eli Lilly and Company (6) · Abbott (5) · Wyeth is now a wholly owned subsidiary of Pfizer (4) · Biocad (3) · Centocor, Inc. (3) · Charite University, Berlin, Germany (3) · Janssen Research & Development, LLC (3) · Merck Sharp & Dohme LLC (3) · Pfizer (3) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (3) · UCB Biopharma SRL (3) · AbbVie (2) · AbbVie (prior sponsor, Abbott) (2) · Amgen (2)
Germany (33) · United States (31) · Czechia (28) · China (27) · France (26) · United Kingdom (26) · Russia (24) · Spain (24) · Belgium (23) · Poland (23) · Netherlands (21) · Canada (20) · Bulgaria (19) · South Korea (19) · Taiwan (15)
Chunde Bao (2) · Joachim Sieper, Prof. (2) · Roman Ivanov, PhD (2)
PMID 41965705, PMID 34618347, PMID 31203228, PMID 33722947, PMID 35305260, PMID 36792107, PMID 30473179, PMID 32352653, PMID 33227175, PMID 33351179, PMID 34773130, PMID 35429281, PMID 36282526, PMID 38488976, PMID 40194794, PMID 40694276, PMID 41039829, PMID 41125403, PMID 41314667, PMID 41417207, PMID 41807031, PMID 42128532, PMID 42297437, PMID 42386286, PMID 19703304, PMID 21600054, PMID 23765873, PMID 26699169, PMID 28544533, PMID 30225992, PMID 30564451, PMID 31254223, PMID 31685553, PMID 33252266, PMID 34538257, PMID 34853086, PMID 35188180, PMID 36649967, PMID 36995469, PMID 37793792, PMID 38599650, PMID 38834351, PMID 39133438, PMID 39406403, PMID 40489668, PMID 42228347, PMID 42605056, PMID 15692973, PMID 15843448, PMID 16342093
2015 (8), 2009 (5), 2017 (3), 2019 (3), 2014 (2), 2016 (2), 2018 (2), 2023 (2), 2008 (1)